KLK3 and prostate cancer: Another study reported that BBI is an anti-carcinogenic serine protease inhibitor that may obstruct the protease activity of prostate-specific antigen (PSA) and the development of human prostate cancer xenografts in nude mice (Wan et al., 1999b).